Lucentis (Ranibizumab)

ranibizumab 1.65 mg/0.165 mL injection, 0.165 mL syringe · INJECTION · PBS code 13134G

STREAMLINED

What it costs

AU$689.04 PBS-determined price per 1 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2022-11-01.
• Repeats: 5.
• PBS program: GE.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Proliferative diabetic retinopathy (PDR) and/or Diabetic macular oedema (DMO)

Continuing treatment

Patient must have previously received PBS-subsidised treatment with this drug for this condition for the same eye; AND

The treatment must be the sole PBS-subsidised therapy for this condition; AND

The treatment must be as monotherapy; or

The treatment must be in combination with laser photocoagulation; AND

Must be treated by an ophthalmologist or by an accredited ophthalmology registrar in consultation with an ophthalmologist.

Sponsor: Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.